3 Stocks Underperforming Today In The Drugs Industry
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.All three major indices are trading up today with the Dow Jones Industrial Average (^DJI) trading up 18 points (0.1%) at 16,551 as of Wednesday, April 2, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,684 issues advancing vs. 1,250 declining with 198 unchanged.The Drugs industry currently is unchanged today versus the S&P 500, which is up 0.2%. Top gainers within the industry include Dr. Reddy Laboratories (RDY), up 2.7%, AbbVie (ABBV), up 1.5%, Pfizer (PFE), up 0.8%, Shire (SHPG), up 0.7% and Novo Nordisk A/S (NVO), up 0.6%.TheStreet would like to highlight 3 stocks pushing the industry lower today:3. GlaxoSmithKline (GSK) is one of the companies pushing the Drugs industry lower today. As of noon trading, GlaxoSmithKline is down $0.46 (-0.9%) to $52.84 on heavy volume. Thus far, 2.0 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $52.82-$53.08 after having opened the day at $52.93 as compared to the previous trading day's close of $53.30. GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, such as vaccines, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $129.7 billion and is part of the health care sector. Shares are down 0.2% year-to-date as of the close of trading on Tuesday. Currently there is 1 analyst that rates GlaxoSmithKline a buy, no analysts rate it a sell, and 7 rate it a hold.TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, increase in stock price during the past year, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full GlaxoSmithKline Ratings Report now.STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV